Absci vs Microbiotica

Side-by-side comparison of AI visibility scores, market position, and capabilities

Microbiotica leads in AI visibility (39 vs 30)
Absci logo

Absci

GrowthBiotechnology

AI Drug Creation

Absci is an AI drug creation company that combines generative AI with a synthetic biology platform to design novel therapeutic proteins from the ground up.

AI VisibilityBeta
Overall Score
D30
Category Rank
#1 of 1
AI Consensus
75%
Trend
up
Per Platform
ChatGPT
26
Perplexity
37
Gemini
29

About

Absci is a publicly traded AI drug creation company founded in 2011 that went public in 2021 and has repositioned around generative AI for drug design. The company operates an integrated platform that uses generative AI to design novel antibodies and proteins, then validates them using high-throughput expression and biological assay systems in its own wet lab infrastructure. Absci's approach treats drug discovery as a generative design problem, using AI to propose protein sequences with desired therapeutic properties and then rapidly testing millions of candidates to identify viable drug leads. The company has established drug creation partnerships with major pharmaceutical companies including AstraZeneca, Merck, and EQT Life Sciences. Absci's technical differentiation lies in its ability to close the loop between AI-generated protein designs and experimental validation at unprecedented scale. The company represents a new category of AI-native biopharmaceutical company that combines computational and wet-lab capabilities to create drugs not discoverable through traditional means.

Full profile
Microbiotica logo

Microbiotica

EmergingBioTech

Microbiome Therapeutics

Microbiotica raised $105M Series C in 2025 for its gut microbiome platform linking bacterial strains to disease, enabling live biotherapeutic products for cancer immunotherapy and IBD.

AI VisibilityBeta
Overall Score
D39
Category Rank
#1 of 2
AI Consensus
75%
Trend
up
Per Platform
ChatGPT
47
Perplexity
43
Gemini
47

About

Microbiotica applies genomics and machine learning to map the gut microbiome's causal role in disease, then develops live biotherapeutic products (LBPs) targeting the specific bacterial strains responsible. The company's Reference Microbiome database — built from thousands of patient samples — is the world's most comprehensive catalog of gut bacteria linked to disease outcomes, providing a systematic foundation for microbiome drug discovery.

Full profile

AI Visibility Head-to-Head

30
Overall Score
39
#1
Category Rank
#1
75
AI Consensus
75
up
Trend
up
26
ChatGPT
47
37
Perplexity
43
29
Gemini
47
31
Claude
42
30
Grok
37

Key Details

Category
AI Drug Creation
Microbiome Therapeutics
Tier
Growth
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Absci
AI Drug Creation
Only Microbiotica
Microbiome Therapeutics

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.